A Clinical Trial to Evaluate a Melanoma Helper Peptide Vaccine Plus Dabrafenib and Trametinib
Clinical trial NCT02382549 · TERMINATED
Trial details
- NCT number
- NCT02382549
- Sponsor
- Craig L Slingluff, Jr
- Status
- TERMINATED
- Phase
- Early Phase 1
- Study type
- INTERVENTIONAL
- Start date
- 2016-04-01
- Primary completion
- 2022-02-28
- Enrollment
- 8
Track trials programmatically
Sponsors, conditions and status changes through the Atlas API.